BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/18/2026 3:51:56 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-03-26 03:45 |
|
Peer-Review Started |
|
2026-03-26 03:45 |
|
First Decision by Editorial Office Director |
|
2026-06-10 05:46 |
|
Return for Revision |
|
2026-06-10 05:46 |
|
Revised |
|
2026-06-23 07:59 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-07-09 02:35 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-07-09 08:36 |
|
Articles in Press |
|
2026-07-09 08:36 |
|
Edit the Manuscript by Language Editor |
|
2026-07-14 13:06 |
|
Typeset the Manuscript |
|
2026-08-11 00:41 |
|
Publish the Manuscript Online |
|
2026-08-18 03:51 |
| ISSN |
1948-5182 (online) |
| Open Access |
Open-Access: This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Second-line treatment of primary biliary cholangitis: To whom, what molecule, and when
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sylvia Drazilova, Peter Jarcuska, Tomas Koky, Martin Harhovsky, Slavomira Komarova, Jan Vasil and Martin Janicko |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Peter Jarcuska, MD, PhD, Professor, 2nd Department of Internal Medicine, PJ Safarik University, Faculty of Medicine and L Pasteur University Hospital, Trieda SNP 1, Kosice 04011, Slovakia. peter.jarcuska@upjs.sk |
| Key Words |
Primary biliary cholangitis; Ursodeoxycholic acid; Second-line treatment; Elafibranor; Seladelpar; Therapeutic response |
| Core Tip |
Primary biliary cholangitis (PBC) is a disease with increasing prevalence, particularly in developed countries. First-line treatment of choice is ursodeoxycholic acid (UDCA), but only about two-thirds of patients achieve biochemical response. UDCA nonresponders have a higher risk of liver cirrhosis decompensation and poorer transplant-free survival. These patients should be considered for second-line therapy. This review provides a comprehensive overview of second-line treatment indications, selection of the most appropriate medication, timing of therapy initiation, benefits, and adverse effects of therapy, as well as the administration of second-line treatment in specific groups of PBC patients. |
| Publish Date |
2026-08-18 03:51 |
| Citation |
Drazilova S, Jarcuska P, Koky T, Harhovsky M, Komarova S, Vasil J, Janicko M. Second-line treatment of primary biliary cholangitis: To whom, what molecule, and when. World J Hepatol 2026; 18(8): 121491
|
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i8/121491.htm |
| DOI |
https://doi.org/10.4254/wjh.121491 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
